01 May 2026

GLP-1 Benefits Beyond Weight Loss: What the Evidence Now Shows

Key Takeaways

Researchers are documenting unexpected benefits of GLP-1 medications — from heart disease to sleep apnoea to addiction. Here's what the current evidence actually says.

GLP-1 Medications Are Doing Something Unexpected

When semaglutide trials began in earnest in the early 2010s, researchers were primarily interested in blood sugar control. Weight loss was a welcome side effect. Then the weight loss data became so striking it drove an entirely new indication.

Now, as tens of millions of people worldwide have taken these medications for years, researchers are documenting effects that nobody fully anticipated — improvements in heart disease outcomes, liver disease, sleep apnoea, kidney function, addiction behaviour, and possibly dementia risk. Whether all of these benefits hold up under continued scrutiny remains to be seen, but the evidence for several of them is now robust enough to have changed clinical practice and regulatory thinking.

This article covers what the current evidence actually says about GLP-1 benefits beyond weight loss — the proven, the promising, and the still-speculative.

Proven: Cardiovascular Benefit

This is the most robustly established benefit beyond weight loss and glucose control. The SELECT trial, published in 2023, enrolled over 17,000 adults with established cardiovascular disease but without diabetes, and randomised them to semaglutide 2.4mg (Wegovy) or placebo.

The result: semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% over a mean follow-up of 34 months. This was above and beyond the effect that would be expected from weight loss alone.

This finding was significant enough that the US FDA granted Wegovy an additional cardiovascular risk reduction indication. The TGA has received similar applications. For patients with cardiovascular disease and obesity, this data strengthens the case for treatment considerably.

Proven: Kidney Function Protection

The FLOW trial, completed in 2024, demonstrated that semaglutide significantly slowed the progression of chronic kidney disease in patients with type 2 diabetes and CKD. The benefit was large enough that the trial was stopped early on efficacy grounds.

Whether similar benefits extend to people with CKD without diabetes is under investigation, but the mechanism — reduced inflammation, improved metabolic parameters, and lower blood pressure — plausibly applies beyond diabetic nephropathy.

Proven: Non-Alcoholic Fatty Liver Disease (MASLD)

GLP-1 medications have shown consistent and striking effects on non-alcoholic fatty liver disease (now termed MASLD — metabolic dysfunction-associated steatotic liver disease). In the ESSENCE trial, semaglutide produced histological improvement (actual reduction in liver fat and fibrosis on biopsy) in a significant proportion of patients with MASH (the more severe inflammatory form).

Want to find out which GLP-1 is right for you?

Our GPs can compare your options and assess your suitability via bulk billed telehealth. No referral required.

Request an Appointment

This led to regulatory approval in the US and Europe for semaglutide in MASH. For Australians with fatty liver disease, this is an increasingly relevant consideration for their GP.

Strong Evidence: Sleep Apnoea

The SURMOUNT-OSA trials examined tirzepatide (Mounjaro) specifically in obstructive sleep apnoea. The results were remarkable: participants using CPAP therapy saw a ~63% reduction in apnoea-hypopnoea index (AHI) on tirzepatide; those not using CPAP saw a ~55% reduction. A substantial proportion achieved resolution of moderate-to-severe OSA.

These results led to FDA approval of tirzepatide for OSA in adults with obesity. For Australian patients whose sleep apnoea is weight-related, this represents a genuine secondary clinical benefit of treatment.

Emerging Evidence: Addiction and Compulsive Behaviours

One of the more surprising signals emerging from real-world GLP-1 data is a reported reduction in addictive behaviours. Patients and clinicians have reported:

Reduced alcohol consumption and cravings
Reduced nicotine cravings and improved quit rates
Reduced compulsive gambling, shopping, and nail-biting in some patients

The mechanistic hypothesis is that GLP-1 receptors in the brain's reward circuitry (the nucleus accumbens and ventral tegmental area) modulate dopamine-mediated reward responses — reducing the reinforcing value of various addictive stimuli, not just food.

Randomised controlled trials for alcohol use disorder and nicotine dependence are underway. The early results are promising but not yet practice-changing in terms of clinical guidelines.

Early Evidence: Dementia and Neurodegeneration

Observational data from large populations of diabetic patients treated with GLP-1 medications has suggested a possible reduction in dementia incidence compared to patients on other diabetes medications. Mechanistic research in animal models and early human studies suggests potential neuroprotective effects — possibly via reduced neuroinflammation and improved insulin signalling in the brain.

This remains speculative at the clinical practice level. Several large randomised trials are underway specifically examining dementia outcomes. This is an area to watch closely over the next 5–10 years.

What This Means for Australian Patients

For Australian patients considering GLP-1 medications for weight management, the emerging evidence on broader health benefits strengthens the case for treatment in those who are eligible. The medications are no longer just "weight loss drugs" in the clinical sense — they are increasingly recognised as cardiometabolic disease-modifying agents with a widening evidence base.

This does not change the access pathway: you still need a GP assessment and private prescription. But it does mean the clinical conversation has become considerably richer than it was three years ago.

Weight Loss GP Australia's bulk billed telehealth consultations give eligible patients access to GPs who are current on this evidence and can discuss what it means for your individual situation.